Loading clinical trials...
Loading clinical trials...
Comparing the Efficacy and Safety of Decitabine-Fludarabine-busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as Conditioning Regimens for AML-MR
Conditions
Interventions
Decitabine
Fludarabine Injection
+1 more
Locations
1
China
Ruijin Hospital
Shanghai, China
Start Date
June 1, 2024
Primary Completion Date
March 1, 2026
Completion Date
May 1, 2028
Last Updated
June 4, 2024
NCT06420063
NCT06486350
NCT06014489
NCT06027853
NCT04380441
NCT07407140
Lead Sponsor
Ruijin Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions